Mesoblast (ASX:MSB) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Mesoblast's annualized Gross Profit for the quarter that ended in Dec. 2024 was A$0.00 Mil. Mesoblast's average Total Assets over the quarter that ended in Dec. 2024 was A$1,031.59 Mil. Therefore, Mesoblast's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Mesoblast Gross-Profit-to-Asset % Historical Data

The historical data trend for Mesoblast's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Gross-Profit-to-Asset % Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

4.58

0.95

1.52

1.15

0.89

Mesoblast Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Mesoblast's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Mesoblast's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Mesoblast's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Mesoblast Gross-Profit-to-Asset % Calculation

Mesoblast's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2024 )	/	( (Total Assets (A: Jun. 2023 )	+	Total Assets (A: Jun. 2024 ))	/ count )
	=	8.888	/	( (997.428	+	1007.744)	/ 2 )
	=	8.888	/	1002.586
	=	0.89 %

Mesoblast's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (0	+	1031.589)	/ 1 )
	=	0	/	1031.589
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Mesoblast Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Mesoblast's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany LWB1:Germany LWB:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.